Johnson & Johnson

Indian Patent Office's decision on J&J's bedaquiline came on the eve of World Tuberculosis Day, marked on March 24 every year, to raise public awareness & to boost efforts to end the TB epidemic

Shares of the drugmaker were up nearly 1% at $170.28 in trading before the bell

The Bombay High Court on Wednesday quashed two orders passed by the Maharashtra government revoking the license of Johnson & Johnson company to manufacture, sell and distribute its baby powder products, terming them as stringent, unreasonable and unfair. A division bench of Justices Gautam Patel and S G Dige permitted the company to manufacture, sell and distribute the products. The bench passed its order on a petition filed by the company challenging two orders of the state government one dated September 15, 2022 cancelling the license and the second dated September 20, 2022 ordering it to immediately stop the manufacturing and sale of the baby powder product. The bench noted that while maintaining standards of quality and safety are of utmost importance for cosmetic products, at the same time it does not seem reasonable to shut down the whole manufacturing process when there is a slight deviation in one of the products. "The executive cannot use a hammer to kill an ant. Is it ..

Even as it grappled with new viruses, the human race hit another milestone

Johnson and Johnson will spend USD 16.6 billion to buy cardiovascular technology company Abiomed to strengthen its medical device division. The health care giant said on Tuesday that it will pay USD 380 for each Biomed share and also provide another USD 35 per share in cash if some commercial and clinical milestones are met. Abiomed develops technology that treats coronary artery disease and heart failure.

The Bombay High Court has directed the Maharashtra government to hand over to Johnson & Johnson Pvt Ltd a report of the Central Drug Laboratory, Kolkata, based on which the state had cancelled the company's cosmetic manufacturing licence for its Mulund facility for its baby powder. A vacation bench of Justices N J Jamadar and Sharmila Deshmukh passed the decision on Wednesday while hearing a petition filed by the company challenging two orders of the state government - one dated September 15 cancelling the license and the second dated September 20 ordering to immediately stop manufacturing and sale of the company's baby powder product. The orders were passed by the Joint Commissioner and Licensing Authority of the state Food and Drug Administration (FDA). The government based its orders on the report of the Central Drug Laboratory, which found the powder containing higher pH level than prescribed. The company challenged the orders first before the Maharashtra Minister for Food and

The state government body also said that the use of the product may affect the health of the skin of newborn babies

J&J said that it had made the "commercial decision" to transition all its baby powder products to use cornstarch instead of talcum powder

About 135 million more doses of Johnson & Johnson's COVID-19 vaccine from a troubled Baltimore factory will have to be destroyed due to quality problems, Congressional panel leaders said Thursday. The announcement follows a report in May that detailed how more than 400 million vaccine doses made at an Emergent BioSolutions plant had to be trashed. The doses more recently slated for destruction were made between August 2021 and February, the House members said. Johnson & Johnson said in a statement Thursday that no doses produced at the site since the factory restarted have reached the market, and it was ending its agreement with Emergent. The doses had been set aside after they were made. The panel said J&J told it that a batch of the shots failed inspection, which rendered all of them unusable. The factory's problems have hurt vaccinations in areas of the world where vaccines are still in short supply, said US Rep. Jim Clyburn, a South Carolina Democrat and COVID-19 ...

Johnson & Johnson and Momenta Pharmaceuticals lawsuit alleges infringement of two old patents associated with 20mg/ml and 40mg/ml Glatiramer Acetate injection, Natco said in a regulatory filing.

Johnson & Johnson is suspending sales forecasts for its COVID-19 vaccine only a few months after saying the shot could bring in as much as USD 3.5 billion this year. The health care giant said Tuesday that a global supply surplus and demand uncertainty prompted the move, which will not affect the company's operational earnings per share guidance. J&J's one-shot vaccine brought in USD 457 million in global sales during the first quarter, with most of that coming from outside the United States. The vaccine brought in only USD 75 million in sales in the US, or about 25 per cent less than what it rang up after debuting in last year's first quarter. J&J has said it doesn't intend to profit from the vaccine. But it said in January that it could bring in between USD 3 billion and USD 3.5 billion in sales this year, as countries continue to fight variants of the virus. The vaccine brought in USD 2.38 billion in sales last year. Vaccine options from rival drugmakers Pfizer and ...

(Reuters) -Johnson & Johnson said on Tuesday it would halt sale of personal care products in Russia, joining other companies that have limited their business in the country in response to its invasion of Ukraine.

Delivery delays and an uneven demand during last year resulted in the drugmaker narrowly missing its goal of garnering $2.50 billion in vaccine sales in 2021.

Most Americans should be given the Pfizer or Moderna vaccines instead of the Johnson & Johnson shot that can cause rare but serious blood clots, U.S. health advisers recommended Thursday. The strange clotting problem has caused nine confirmed deaths after J&J vaccinations while the Pfizer and Moderna vaccines don't come with that risk and also appear more effective, advisers to the Centers for Disease Control and Prevention said. It's an unusual move and the CDC's director, Dr. Rochelle Walensky, must decide whether to accept the panel's advice. Until now the U.S. has treated all three COVID-19 vaccines available to Americans as an equal choice, since large studies found they all offered strong protection and early supplies were limited. J&J's vaccine initially was welcomed as a single-dose option that could be especially important for hard-to-reach groups like homeless people who might not get the needed second dose of the Pfizer or Moderna options. But the CDC's ...

Most Americans should be given the Pfizer or Moderna vaccines instead of the Johnson & Johnson shot that can cause rare but serious blood clots, U.S. health advisers recommended Thursday. The strange clotting problem has caused nine confirmed deaths after J&J vaccinations while the Pfizer and Moderna vaccines don't come with that risk and also appear to be more effective, advisers to the Centers for Disease Control and Prevention said. It's an unusual move and the CDC's director, Dr. Rochelle Walensky, must decide whether to accept the panel's advice. Until now the U.S. has treated all three COVID-19 vaccines available to Americans as an equal choice, since large studies found they all offered strong protection and early supplies were limited. J&J's vaccine initially was welcomed as a single-dose option that could be especially important for hard-to-reach groups like homeless people who might not get the needed second dose of the Pfizer or Moderna options. But the CDC's ..

Vaccine advisers with the US CDC will meet on Thursday to discuss potentially limiting the use of the Johnson and Johnson vaccine due to persistent blood clot issues

The health-care giant will split off its consumer division in 18 to 24 months, the company said in a statement

Johnson & Johnson is splitting into two companies, separating the division that sells Band-Aids and Listerine, from its medical device and prescription drug business. The company selling prescription drugs and medical devices will keep Johnson & Johnson as its name, the company said Friday. The new consumer health company will house brands including Neutrogena, Aveeno, Tylenol, Listerine, Johnson's, and Band-Aid. A name was not disclosed for the new company. Details are sparse, but the company expect the split to occur in the next two years. The announcement comes just days after General Electric said that it plans to split into three separate companies.

The federal government has canceled a multimillion dollar deal with Emergent BioSolutions, a Maryland-based vaccine manufacturer with facilities in Baltimore that were found to have produced millions of contaminated Johnson & Johnson vaccine doses this spring, the Washington Post reported. Emergent disclosed the development Thursday in a conference call discussing its latest financial results, the Post reported. Emergent said it will forgo about USD 180 million due to the contract's termination, according to the Post. Emergent BioSolutions played a role in the Trump administration's effort to speed up vaccine development and distribution. But after winning a contract from the previous administration, Emergent quickly ran into production problems. In March, ingredients intended for use in producing the Oxford-AstraZeneca vaccine shots contaminated 15 million doses of the Johnson & Johnson vaccine. The problems with the vaccines caused a monthslong delay in production. After ...

Pfizer and BioNTech said a booster shot of their Covid-19 vaccine restored full protection in a large study, results that are likely to bolster the argument for giving a third dose more widely